clinical trial Archives | Be Korea-savvy
Informa Pharma Intelligence Launches New Product Citeline Engage

Informa Pharma Intelligence Launches New Product Citeline Engage

LONDON, Oct. 10 (Korea Bizwire) – Informa Pharma Intelligence today announces Citeline Engage, a new solution allowing contact research organizations (CROs) and sponsors to optimize site selection and increase trial efficiencies to accelerate clinical trial timelines and enable a faster path to market for drugs. Citeline Engage is a first-to-market solution designed specifically to help optimize protocol [...]

Safety and Efficacy of Philips’ Stellarex .035 Low-dose Drug-coated Balloon Demonstrated in Clinical Trials at Three Years

Safety and Efficacy of Philips’ Stellarex .035 Low-dose Drug-coated Balloon Demonstrated in Clinical Trials at Three Years

Amsterdam, the Netherlands and New Orleans, U.S., May 29 (Korea Bizwire) – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced the three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomized clinical trial (EU RCT). These two trials are part of a series of five trials evaluating the [...]

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder

NEW YORK, Jan. 7 (Korea Bizwire) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the [...]

Pharmaceutical Companies Fail to Meet Sales Permit Conditions

Pharmaceutical Companies Fail to Meet Sales Permit Conditions

SEOUL, Nov. 5 (Korea Bizwire) — Pharmaceutical companies are facing controversy as they were found to be avoiding manufacturing certain medicines for which authorities issued sales permits upon condition that they would be used for clinical trials on patients, if market reaction was ‘not good enough’. Rep. Jang Jeong-sook of the ruling Democratic Party, a [...]

Nanobiotix Receives First Tranche Disbursement of 16 Million Euros Financing from European Investment Bank

Nanobiotix Receives First Tranche Disbursement of 16 Million Euros Financing from European Investment Bank

Paris, France and Cambridge, Massachusetts, Oct. 16 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company received an initial 16 million euros as the first disbursement under the previously announced non-dilutive loan from the European Investment Bank [...]

Nanobiotix to Present Positive Results from its Phase II/III Clinical Trial of NBTXR3 in Patients with Soft Tissue Sarcoma (STS) and Other Ongoing Phase I/II Trials at Upcoming ESMO and ASTRO Annual Conferences

Nanobiotix to Present Positive Results from its Phase II/III Clinical Trial of NBTXR3 in Patients with Soft Tissue Sarcoma (STS) and Other Ongoing Phase I/II Trials at Upcoming ESMO and ASTRO Annual Conferences

PARIS, France and CAMBRIDGE, Massachusetts, Sept. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, [...]

SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test

SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test

SYDNEY, Australia, Sept. 25 (Korea Bizwire) — SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers [...]

TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History

TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History

EDMONTON, Alberta, Jul. 9 (Korea Bizwire) — Translational Research In Oncology (TRIO) today announced a collaboration with Novartis on its upcoming phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial will be called NATALEE (New Adjuvant TriAl with LEE). “Ribociclib in combination [...]

Novel Alzheimer’s Disease Candidate Developed by Megabiowood Pending for Clinical Trials at Post Year

Novel Alzheimer’s Disease Candidate Developed by Megabiowood Pending for Clinical Trials at Post Year

SEOUL, Jun. 23 (Korea Bizwire) — Novel Alzheimer’s disease (AD) medication developed by Megabiowood research team is planning for phase I clinical trial in next year. The novel medication is appraised to have high commercial possibilities as its aspects which shows non-cytotoxicity and superior absorbency that solves not only the symptoms but also the cause [...]

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

CAMBRIDGE, United Kingdom, Apr. 16 (Korea Bizwire) — AstraZeneca and MedImmune, its global biologics research and development arm, today presented efficacy and safety data from two Phase I trials evaluating Imfinzi (durvalumab) in combination with tremelimumab in 2nd-line immunotherapy-naïve patients with either non-squamous advanced non-small cell lung cancer (NSCLC) (Study 006) or metastatic urothelial carcinoma [...]